Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need

In response to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, over 200 vaccine candidates against coronavirus disease 2019 (COVID-2019) are under development and currently moving forward at an unparalleled speed. The availability of surrogate endpoints would help to avoid...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Pengfei, Li, Jingxin, Pan, Hongxing, Wu, Yanfei, Zhu, Fengcai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851657/
https://www.ncbi.nlm.nih.gov/pubmed/33531462
http://dx.doi.org/10.1038/s41392-021-00481-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851657/
https://www.ncbi.nlm.nih.gov/pubmed/33531462
http://dx.doi.org/10.1038/s41392-021-00481-y

Ejemplares similares